High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy

Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments.

Source: Molecular Oncology - September 15, 2015 Category: Cancer & Oncology Authors: Paolo Nuciforo, Sheeno Thyparambil, Claudia Aura, Ana Garrido-Castro, Marta Vilaro, Vicente Peg, José Jimenez, Rocio Vicario, Fabiola Cecchi, William Hoos, Jon Burrows, Todd Hembrough, Juan Carles Ferreres, José Perez-Garcia, Joaquin Arribas, Javier Cor Source Type: research